Key Highlights
- Cathie Wood’s firm dumped more than 100K Taiwan Semiconductor Manufacturing shares valued at $40.6M
- The investment firm accumulated approximately 255K Cerebras Systems shares
- ARK purchased over 162K shares in AI-powered healthcare company Tempus AI
- The fund offloaded AMD holdings worth $10.9M across several portfolios
- ARK Innovation ETF has declined 3.81% this year while the S&P 500 gained over 8%
Cathie Wood’s ARK Invest executed significant portfolio adjustments during the past week, reducing its semiconductor holdings while simultaneously increasing stakes in artificial intelligence infrastructure and healthcare technology companies.
The most substantial divestment involved Taiwan Semiconductor Manufacturing Company. Between May 14 and 15, ARK’s portfolio managers sold 100,549 shares of the chip manufacturing giant, representing approximately $40.6 million in total value. Despite this exit, TSMC stock has climbed roughly 35% since the beginning of the year. The semiconductor foundry recently upgraded its global market projection to $1.5 trillion by 2030, an increase from its earlier $1 trillion estimate, with artificial intelligence and high-performance computing anticipated to drive 55% of future demand.
Taiwan Semiconductor Manufacturing Company Limited, TSM
TSMC delivered impressive first-quarter 2026 financial results, reporting revenue growth of 35.1% and net income expansion of 58.3%. The company’s chief executive characterized AI-related demand as “extremely robust.” Notably, TSMC doesn’t currently rank among ARK’s ten largest positions.
ARK simultaneously divested approximately 62K Advanced Micro Devices shares valued at $10.9M, alongside more than 57K Teradyne shares totaling $20.7M. These transactions occurred as the iShares Semiconductor ETF experienced a roughly 4% decline on May 15.
Strategic Acquisitions in AI and Medical Technology
On the acquisition front, ARK accumulated around 255K Cerebras Systems shares, representing one of its most significant single-week purchases. Cerebras specializes in AI compute infrastructure and has generated increasing attention from the investment community.
The firm also acquired more than 162K Tempus AI shares, targeting a company that leverages artificial intelligence for healthcare applications and diagnostic solutions. ARKK added 132K Intellia Therapeutics shares and 52K Natera shares, maintaining its consistent focus on precision medicine investments.
Within the financial technology sector, ARK purchased nearly 42K Circle Internet shares distributed across three separate funds, expanding its presence in digital payment systems and cryptocurrency-related financial infrastructure.
ARK further acquired over 61K Kodiak AI shares and 183K Kratos Defense shares, extending a deliberate strategy of accumulating defense technology positions.
Fund Performance and Strategic Vision
The Ark Innovation ETF, Wood’s primary investment vehicle, has declined 3.81% in 2026 year-to-date, underperforming the S&P 500’s gain exceeding 8%. Examining a five-year timeline, ARKK has generated an annualized return of -6.25%, contrasting with the S&P 500’s 13.80% performance during the same period, based on Morningstar data.
Despite this performance gap, Wood maintains her optimistic long-term perspective. She has characterized the present moment as a “great acceleration” propelled by artificial intelligence and emerging technologies, while rejecting suggestions that current market conditions resemble a speculative bubble.
“AI training costs are dropping 75% per year,” Wood stated during a recent Bloomberg podcast appearance, emphasizing that inference costs are declining at an even more rapid pace.
Investor appetite for ARK’s investment strategies appears resilient. The Ark Innovation ETF attracted approximately $1.48 billion in net capital inflows during the five-day period ending May 14, according to data from ETF analytics firm VettaFi.
As of May 15, ARK’s largest portfolio allocations include Tesla at 11.16%, AMD at 5.57%, and Circle Internet at 5.23%.



